Related Experiment Video
Updated: Feb 13, 2026

Development and Functional Characterization of Murine Tolerogenic Dendritic Cells
Published on: May 18, 2018
Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand?
Eros Marín1,2, Maria Cristina Cuturi1,2, Aurélie Moreau1,2
1Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France.
Tolerogenic monocyte-derived dendritic cells (Tol-MoDCs) offer a promising cell therapy to induce specific immune tolerance in organ transplantation, potentially reducing reliance on broad immunosuppressive drugs and their associated risks.
Area of Science:
- Immunology
- Transplantation Science
- Cell Therapy
Background:
- Solid organ transplantation has advanced, but graft rejection persists without immunosuppressive drugs (IS).
- IS drugs prevent rejection but increase risks of cancer and infection due to their lack of specificity.
- Cell therapies present a novel approach to minimize IS use and achieve graft-specific tolerance.
Purpose of the Study:
- To review the characteristics and mechanisms of tolerogenic monocyte-derived dendritic cells (Tol-MoDCs) and rodent tolerogenic bone marrow-derived DCs (Tol-BMDCs).
- To discuss the potential of Tol-MoDCs in transplantation, building on evidence from rodent and non-human primate models.
- To explore the translation of Tol-MoDCs into clinical applications for transplantation.
Main Methods:
- Review of scientific literature on tolerogenic dendritic cells (Tol-DCs) and their application in transplantation models.
- Analysis of data from preclinical studies in rodents and non-human primates.
- Examination of ongoing and completed clinical trials involving Tol-MoDCs.
Main Results:
- Tolerogenic dendritic cells (Tol-DCs), particularly Tol-MoDCs, demonstrate the ability to induce specific antigen presentation and immune tolerance.
- Preclinical studies in rodents and non-human primates support the immunoregulatory potential of Tol-BMDCs in transplantation.
- Tol-MoDCs have shown safety in clinical trials for autoimmune diseases and are now being evaluated in early-phase transplantation trials.
Conclusions:
- Tolerogenic monocyte-derived dendritic cells (Tol-MoDCs) are a promising cell therapy for inducing allograft-specific tolerance in transplantation.
- Minimizing immunosuppressive drug use through cell therapy like Tol-MoDCs could improve long-term graft survival and patient safety.
- Further clinical evaluation of Tol-MoDCs in transplantation is warranted to establish their efficacy and widespread application.
More Related Videos
06:09Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
Published on: June 22, 2016
11:34A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Related Concept Videos
Structures of Solids
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Standing Waves
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Modes of Standing Waves - I
Modes of Standing Waves: II
For a tube open at one end and closed at the other filled with air, the modes are such that there is always an antinode at the open end and a node at the closed end....